JP2025503707A5 - - Google Patents

Info

Publication number
JP2025503707A5
JP2025503707A5 JP2024542044A JP2024542044A JP2025503707A5 JP 2025503707 A5 JP2025503707 A5 JP 2025503707A5 JP 2024542044 A JP2024542044 A JP 2024542044A JP 2024542044 A JP2024542044 A JP 2024542044A JP 2025503707 A5 JP2025503707 A5 JP 2025503707A5
Authority
JP
Japan
Application number
JP2024542044A
Other languages
Japanese (ja)
Other versions
JPWO2023139107A5 (https=
JP2025503707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/051100 external-priority patent/WO2023139107A1/en
Publication of JP2025503707A publication Critical patent/JP2025503707A/ja
Publication of JPWO2023139107A5 publication Critical patent/JPWO2023139107A5/ja
Publication of JP2025503707A5 publication Critical patent/JP2025503707A5/ja
Pending legal-status Critical Current

Links

JP2024542044A 2022-01-18 2023-01-18 ガレクチン-10抗体 Pending JP2025503707A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB202200597 2022-01-18
GB2200597.9 2022-01-18
PCT/EP2023/051100 WO2023139107A1 (en) 2022-01-18 2023-01-18 Galectin-10 antibodies

Publications (3)

Publication Number Publication Date
JP2025503707A JP2025503707A (ja) 2025-02-04
JPWO2023139107A5 JPWO2023139107A5 (https=) 2026-03-03
JP2025503707A5 true JP2025503707A5 (https=) 2026-03-03

Family

ID=85037098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542044A Pending JP2025503707A (ja) 2022-01-18 2023-01-18 ガレクチン-10抗体

Country Status (10)

Country Link
US (1) US20250059285A1 (https=)
EP (1) EP4466070A1 (https=)
JP (1) JP2025503707A (https=)
KR (1) KR20240133711A (https=)
CN (1) CN118488967A (https=)
AU (1) AU2023208882A1 (https=)
CA (1) CA3236108A1 (https=)
IL (1) IL314367A (https=)
MX (1) MX2024006275A (https=)
WO (1) WO2023139107A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118206657B (zh) * 2023-12-29 2025-03-07 康旭生物科技(深圳)有限公司 一种半乳糖凝集素-3的抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CN112142843B (zh) 2013-12-24 2024-10-18 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
GB201707484D0 (en) 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.

Similar Documents

Publication Publication Date Title
JP2025503707A5 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
JP2024541911A5 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022000931U2 (https=)
BY13175U (https=)
BY13167U (https=)
CN307045627S (https=)
CN307044977S (https=)
CN307044357S (https=)
BY23965C1 (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13143U (https=)
CN307045606S (https=)
CN307046354S (https=)